Tazemetostat (EPZ6438) is an FDA-approved drug with high selectivity towards EZH2, which demonstrates a significant reduction in tumor weight in the TH-MYCN mouse model with no related adverse effect [35]. The gene discussed is EZH2; the disease is neoplasm.